Biodesix announced recently that the United States Patent and Trademark Office (USPTO) has awarded to the company patent number 7,736,905. The patent relates to the company’s first product Veristrat, which is used to identify non-small cell lung cancer patients likely to respond to therapy with erlotinib (Tarceva). Specifically, the patent is for the [...]
CBSA’s May BioBreakfast allowed two of Colorado’s 2009 Bioscience success stories to share their stories. First up was Paul Beresford of Biodesix, a company playing in the diagnostic space. Instead of focusing on evaluating a single analyte to diagnose disease, Biodesix seeks to predict treatment response through the evaluation of many analytes run through an [...]
October 29, 2009 – 2:23 pm
“One data point doesn’t tell you very much in most cases,” comments David Brunel, CEO of Biodesix, a medical diagnostics company based in Broomfield, Colorado. This principle guides Biodesix’s approach to developing diagnostics which aim to indentify a patient’s expected response to a particular therapeutic. Biodesix’s technology evaluates multiple biomarkers – [...]
August 12, 2009 – 5:12 pm
August’s Rockies Venture Club event offered brief presentations from two Colorado companies that have been successful in raising capital. BioDesix, presented by CFO Frank Ronchetti, recently launched its first commercial product VeriStrat, a blood-based diagnostic that falls under the umbrella of personalized medicine. The VeriStrat test identifies lung cancer patients who are likely to [...]
BioDesix, Inc released additional data related to the use of its VeriStrat test in head and neck cancer. The data demonstrates that VeriStrat showed predictive value in indentifying patients who were likely to benefit from treatment with epidermal growth factor inhibitors (EGFRIs). An overall survival benefit was observed in patients identified by the [...]
BioDesix, Inc. announced the commercial availability of its VeriStrat test for lung cancer patients. Utilizing a blood sample, the test uses mass spectrometry and proprietary algorithms to categorize patients into two groups based on expected outcomes from treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as Tarceva (erlotinib). In a 460 patient [...]
